Brief Title
Combined HCC-MFCCC
Official Title
Survival After Hepatectomy for Combined Hepatocellular Cholagiocarcinoma
Brief Summary
Combined hepatocellular and mass-forming cholangiocarcinoma (cHCC-MFCCC) is a rare tumor. The aim of this study was the analysis of the outcome comparing such tumor with classic hepatocellular carcinoma (HCC) and mass-forming cholangiocarcinoma (MFCCC).
Detailed Description
The institutional prospectively maintained database was queried, and 20 patients with cHCC-MFCCC were identified. A 2:1 match was performed with 40 patients operated in the same period for HCC, and with 40 operated for MFCCC. Only T1 or T2 patients N0 M0 were considered. Primary endpoint was the overall survival (OS) and disease-free survival (DFS).
Study Type
Observational
Primary Outcome
Survival analysis
Condition
Liver Carcinoma
Intervention
Hepatectomy
Study Arms / Comparison Groups
cHCC-MFCCC
Description: Patients affected by combined HCC-MFCCC
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Procedure
Estimated Enrollment
100
Start Date
January 1, 2004
Completion Date
May 15, 2017
Primary Completion Date
December 31, 2014
Eligibility Criteria
Inclusion Criteria: - positive histology for cHCC-MFCCC, HCC, and MFCCC - complete clinical, surgical, pathological and follow-up data. Exclusion Criteria: - patients preoperatively treated with chemotherapy, radiofrequency ablation or trans-arterial therapies were excluded. - patients operated for recurrent disease and/or with non-radical surgery - patients with missing data were also excluded
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
, ,
Administrative Informations
NCT ID
NCT03178409
Organization ID
cHCC-MFCCC
Responsible Party
Principal Investigator
Study Sponsor
University of Milan
Study Sponsor
, ,
Verification Date
June 2017